Update-1 November 28 Another nasty day for biotech A bit of a selloff in the market indices today with the NASDAQ down 0.58% and the S&P down 0.53%. The highly touted Russell 2000 (IWM) was down 1.3% after a 15 day rally. But the real wreck was in biotech with the XBI down 3.09% and […]
Update-3… 10/28 9:30 am… No Relief From Earnings- Biotech Stocks Get Crushed By More Pricing Commentary on Earnings Calls Amgen (AMGN) down 11% on pipeline, revenue growth, Enbrel pricing concerns despite beat. Softer pricing environment from McKesson (MCK). All large caps are red except Alexion (ALXN) up 1.83%. Abbvie (ABBV) down 6% on revenue miss;Humira […]
BIO International 2016 : “Imagine Who You will Meet” was an Appropriate Theme Healthcare Disruption Is Creating Reform BIO 2016 was an excellent meeting as usual because of the opportunity to hear thought leaders, policy makers, scientists and make connection with thousands of participants from around the world. Healthcare disruption, sustainability and patient access were […]
Update-1 After Close 6/10/16 –Biotech Rally Fizzles in Broad Sell-Off The market continued to sell off during the day with only a little bounce off the lows. The material and energy sectors got hit hard down 2.4 and 1.6% respectively but weakness was across the board. Healthcare stocks were off 1.3% and technology down 1.23%. […]
Biotech Bear Market: XLV —A Large Cap Healthcare ETF Outperforms We have compared the performance of top mutual funds in the past and thought it would be interesting to see what happens in a bear market which began in September of 2015. Our last review was in February of 2015 when the bull market was in full swing. […]
Expect Modest Rally in Biotechs Through Q1 Earnings As of mid-day trading 1P EDT with flat NASDAQ Update at close: biotechs held onto gains despite a mild sell-off for the Dow and S&P with NASDAQ flat. Biogen (BIIB) gained a tad more up 5.16%. From here we’d like to see more rotation into healthcare and […]
Biotech Rally Loses Momentum But Still Up for the Week IBB up 3.37 % , XBI up 5.04% , XLV up 0.77% this week. Investors took profits today despite all of the media focus and renewed excitement for the long term potential of new blockbuster drugs. The rally began Wednesday with the news that the […]
3/22/16…Update Biotech Rally Enters Fourth Day-Green Screen XBI up 7.34% Over Five Days to $52.49 Our new picks were up today: ABBV,BLUE, BMY,GILD. But Gilead Sciences (GILD) was down after hours as Merck (MRK) HCV patents were found valid in dispute. A jury will decide how much Gilead owes to Merck. Busted Biotechs are Still […]
Biotech Stocks Off Lows Tracking Crude and Energy sector… 11.45 a EST Can healthcare stocks uncouple from energy and macro? Individual biotech stocks look very tradable with green catching up with red. But biotech stocks defy fundamental analysis with current random hourly volatility. IBB up 0.12% off bottom of $254 XBI up 0.20% XLE up […]
Have we reached a tradeable bottom in the biotech bear market? Today’s tape showed good volume but gains faded late in session. NASDAQ up 0.35% XLV up 0.88%-healthcare is the leading sector The biotech market bounced back early today in a broad rally then faded with the IBB up 0.625 % […]
PO Box 3701
Manhattan Beach CA 90266
(310) 871-1231
rod@rayno.com
Rod Raynovich is the founder of Raygent Associates, a management consulting firm providing business development and strategic marketing services in the life science and medical device area. He publishes his thoughts and analysis on the biotech industry at www.raygent.com.